How to calculate the dose of chemotherapy
Open Access
- 16 April 2002
- journal article
- case report
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (8) , 1297-1302
- https://doi.org/10.1038/sj.bjc.6600139
Abstract
Body surface area-dosing does not account for the complex processes of cytotoxic drug elimination. This leads to an unpredictable variation in effect. Overdosing is easily recognised but it is possible that unrecognised underdosing is more common and may occur in 30% or more of patients receiving standard regimen. Those patients who are inadvertently underdosed are at risk of a significantly reduced anticancer effect. Using published data, it can be calculated that there is an almost 20% relative reduction in survival for women receiving adjuvant chemotherapy for breast cancer as a result of unrecognised underdosing. Similarly, the cure rate of cisplatin-based chemotherapy for advanced testicular cancer may be reduced by as much as 10%. The inaccuracy of body surface area-dosing is more than an inconvenience and it is important that methods for more accurate dose calculation are determined, based on the known drug elimination processes for cytotoxic chemotherapy. Twelve rules for dose calculation of chemotherapy are given that can be used as a guideline until better dose-calculation methods become available. Consideration should be given to using fixed dose guidelines independent of body surface area and based on drug elimination capability, both as a starting dose and for dose adjustment, which may have accuracy, safety and financial advantages.Keywords
This publication has 36 references indexed in Scilit:
- Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane ReceptorJournal of Biological Chemistry, 2002
- Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trialThe Lancet, 2000
- Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast CancerNew England Journal of Medicine, 2000
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- The human drug metabolizing cytochromes P450Journal of Pharmacokinetics and Biopharmaceutics, 1996
- Influence of clinicopathological variables on CYP protein expression in human liverJournal of Gastroenterology and Hepatology, 1996
- Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal functionCancer Treatment Reviews, 1995
- A Phase I/II Study of Dose and Administration of Non-Glycosylated Bacterially Synthesized G-M CSF in Chemotherapy-Induced Neutropenia in Patients with Non-Hodgkin's LymphomasLeukemia & Lymphoma, 1992
- Amputation and Adriamycin in Primary OsteosarcomaNew England Journal of Medicine, 1974